The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.

British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab ...

Funding for climate tech has contracted in recent years. What makes Gothenburg so unique in its ability to fund, scale and ...

Investment company RTW Investments has launched a new biotech company called Prolium Bioscience, to advance the development ...

MHRA’s independence also questioned during Commons debate, with regulator accused of being too close to companies it ...

Quantum computing stocks landed on investors' radars late last year when Alphabet announced a huge breakthrough with one of ...

Dr. Patrick Hemmons travelled to Seattle, Wash., to get an RSV shot for his daughter. He says he hopes to see ...

Sir Chris Whitty tells the Covid-19 Inquiry the NHS has 'slipped backwards' since the pandemic at sharing vital patient data, ...

Tokyo: Daichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the ...

Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a ...

Trapped-ion quantum computing leader IonQ (NYSE: IONQ) is emerging as a potential leader in the commercialization of quantum ...